

Sylvain Audia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8029583/publications.pdf>

Version: 2024-02-01

98
papers

3,612
citations

147801

31
h-index

149698

56
g-index

123
all docs

123
docs citations

123
times ranked

4374
citing authors

#	ARTICLE	IF	CITATIONS
1	Adrenal Insufficiency Revealing a Bilateral Adrenal Hemorrhage-Adrenal Infarction Related to Antiphospholipid Syndrome. <i>American Journal of Medicine</i> , 2022, 135, 194-195.	1.5	2
2	Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD. <i>Frontiers in Immunology</i> , 2022, 13, 827712.	4.8	2
3	T-cell immune response predicts the risk of critical SARS-Cov2 infection in hospitalized COVID-19 patients. <i>European Journal of Internal Medicine</i> , 2022, 102, 104-109.	2.2	4
4	High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, E43-E46.	4.1	11
5	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2021, 10, e1332.	3.8	18
6	Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect. <i>Oncoimmunology</i> , 2021, 10, 1880046.	4.6	6
7	Emerging Therapies in Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1004.	2.4	33
8	Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	40
9	Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. <i>HemaSphere</i> , 2021, 5, e574.	2.7	45
10	Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review.. <i>Frontiers in Medicine</i> , 2021, 8, 678456.	2.6	3
11	Myocardial infarction during giant cell arteritis: A cohort study. <i>European Journal of Internal Medicine</i> , 2021, 89, 30-38.	2.2	8
12	Mucosal-associated invariant T cells in Giant Cell Arteritis. <i>Journal of Autoimmunity</i> , 2021, 121, 102652.	6.5	5
13	Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. <i>Haematologica</i> , 2021, 106, 3198-3201.	3.5	20
14	Endovascular stenting for chronic femoro-iliac venous obstructive disease: Clinical efficacy and short-term outcomes. <i>Diagnostic and Interventional Imaging</i> , 2020, 101, 15-23.	3.2	17
15	Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation. <i>Platelets</i> , 2020, 31, 536-540.	2.3	13
16	Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism. <i>Clinical Colorectal Cancer</i> , 2020, 19, 57-60.	2.3	3
17	Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2020, 9, 1998.	2.4	10
18	Evansâ€™ Syndrome: From Diagnosis to Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3851.	2.4	50

#	ARTICLE	IF	CITATIONS
19	Full-field optical coherence tomography for the diagnosis of giant cell arteritis. PLoS ONE, 2020, 15, e0234165.	2.5	6
20	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology, 2020, 95, e70-e78.	1.1	142
21	A great masquerader disease. European Journal of Internal Medicine, 2020, 78, 133-134.	2.2	1
22	Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. Journal of the American Academy of Dermatology, 2020, 83, 1759-1763.	1.2	18
23	Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study. Blood, 2020, 136, 12-13.	1.4	1
24	Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. American Journal of Hematology, 2019, 94, 1314-1324.	4.1	55
25	Bortezomib and dexamethasone, an original approach for treating multirefractory warm autoimmune haemolytic anaemia. British Journal of Haematology, 2019, 187, 124-128.	2.5	29
26	Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study. Internal Medicine Journal, 2019, 49, 1154-1162.	0.8	15
27	HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nature Communications, 2018, 9, 1431.	12.8	21
28	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. Journal of Rheumatology, 2018, 45, 425-429.	2.0	23
29	Biological treatments in giant cell arteritis & Takayasu arteritis. European Journal of Internal Medicine, 2018, 50, 12-19.	2.2	30
30	Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS ONE, 2018, 13, e0207218.	2.5	49
31	Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia. Journal of Autoimmunity, 2018, 93, 139-144.	6.5	7
32	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. European Journal of Internal Medicine, 2018, 57, 96-104.	2.2	29
33	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology, 2018, 57, 1432-1438.	1.9	38
34	Association of hidradenitis suppurativa and familial Mediterranean fever: A case series of 6 patients. Joint Bone Spine, 2017, 84, 159-162.	1.6	28
35	Fcγ3 receptor expression on splenic macrophages in adult immune thrombocytopenia. Clinical and Experimental Immunology, 2017, 188, 275-282.	2.6	38
36	Pathogenesis of immune thrombocytopenia. Autoimmunity Reviews, 2017, 16, 620-632.	5.8	249

#	ARTICLE	IF	CITATIONS
37	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
38	Recent advances in our understanding of giant cell arteritis pathogenesis. <i>Autoimmunity Reviews</i> , 2017, 16, 833-844.	5.8	150
39	Physiopathologie des artérites à cellules géantes. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 215-222.	0.0	2
40	Anti-Mi2 dermatomyositis revisited: pure DM phenotype with muscle fiber necrosis and high risk of malignancy. <i>Neuromuscular Disorders</i> , 2017, 27, S153.	0.6	2
41	Ophthalmic manifestations in IgG4-related disease. <i>Medicine (United States)</i> , 2017, 96, e6205.	1.0	65
42	Diagnosis of hyperferritinemia in routine clinical practice. <i>Presse Medicale</i> , 2017, 46, e329-e338.	1.9	29
43	A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm autoimmune hemolytic anemia in adults (the RAHA study). <i>American Journal of Hematology</i> , 2017, 92, 23-27.	4.1	84
44	B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2017, 77, 89-95.	6.5	33
45	T Cell Polarization toward TH2/TFH2 and TH17/TFH17 in Patients with IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2017, 8, 235.	4.8	81
46	Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients. <i>PLoS ONE</i> , 2017, 12, e0187296.	2.5	15
47	Endovascular stent placement for chronic post-thrombotic symptomatic ilio-femoral venous obstructive lesions: a single-center study of safety, efficacy and quality-of-life improvement. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016, 6, 342-352.	2.0	23
48	Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. <i>Medicine (United States)</i> , 2016, 95, e3027.	1.0	24
49	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. <i>Blood</i> , 2016, 128, 1625-1630.	1.4	78
50	Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement. <i>Medicine (United States)</i> , 2016, 95, e4238.	1.0	36
51	Involvement and prognosis value of CD8 + T cells in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 72, 73-83.	6.5	56
52	Is there still a place for "old therapies" in the management of immune thrombocytopenia?. <i>Revue De Medecine Interne</i> , 2016, 37, 43-49.	1.0	27
53	High Incidence of Venous Thromboembolism Events during Warm Autoimmune Hemolytic Anemia. <i>Blood</i> , 2016, 128, 2448-2448.	1.4	1
54	A Multicenter Study Evaluating the Safety of Romiplostim at Maximal Dosage for Emergency Bleeding Situations in Immune Thrombocytopenia. <i>Blood</i> , 2016, 128, 2541-2541.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Thrombopoietin-Receptor Agonist in Systemic Lupus Erythematosus Associated Immune Thrombocytopenia: Results of the 16 Patients from the French Cohort. <i>Blood</i> , 2016, 128, 2542-2542.	1.4	3
56	Safety and Efficacy of PRTX-100, a Highly Purified Form of Staphylococcal Protein A, in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016, 128, 4929-4929.	1.4	7
57	T Lymphocyte Plasticity in Autoimmunity and Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-2.	1.9	4
58	T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	5
59	Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3 ⁺ positive CD8 ⁺ T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1614-1624.e4.	2.9	29
60	Stroke associated with giant cell arteritis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 216-221.	1.9	95
61	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. <i>Journal of Autoimmunity</i> , 2015, 62, 22-30.	6.5	40
62	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimmune Hemolytic Anemia in Adults. <i>Blood</i> , 2015, 126, 3338-3338.	1.4	1
63	A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists. <i>Blood</i> , 2015, 126, 3460-3460.	1.4	2
64	Splenic and Circulating Human T Follicular Helper Cell Regulation By B Cell Depleting Therapy during Immune Thrombocytopenia. <i>Blood</i> , 2015, 126, 8-8.	1.4	8
65	Does Tocilizumab Indeed Reduce the Frequency of Th17 Cells? Comment on the Article by Thiolat et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 2639-2640.	5.6	1
66	Severe cardiomyopathy revealing antineutrophil cytoplasmic antibodies ⁻ negative eosinophilic granulomatosis with polyangiitis. <i>Internal Medicine Journal</i> , 2014, 44, 928-931.	0.8	7
67	The Reversed Halo Sign: Pathognomonic Pattern of Pulmonary Mucormycosis in Leukemic Patients With Neutropenia?. <i>Clinical Infectious Diseases</i> , 2014, 58, 672-678.	5.8	133
68	Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. <i>European Journal of Internal Medicine</i> , 2014, 25, 837-842.	2.2	16
69	Is TNF- α really involved in giant cell arteritis pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e1-e1.	0.9	11
70	Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. <i>Blood</i> , 2014, 124, 2858-2866.	1.4	64
71	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. <i>Blood</i> , 2014, 124, 3228-3236.	1.4	142
72	Emergence of Long-Lived Autoreactive Plasma Cells in the Spleen of Primary Warm Auto-Immune Hemolytic Anemia Patients Treated with Rituximab. <i>Blood</i> , 2014, 124, 569-569.	1.4	1

#	ARTICLE	IF	CITATIONS
73	P.14.2 Dermatomyositis associated with MDA-5 antibodies: Report of the first European series. Neuromuscular Disorders, 2013, 23, 813-814.	0.6	1
74	Reply. Arthritis and Rheumatism, 2013, 65, 1134-1135.	6.7	1
75	Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigoleet al. Annals of the Rheumatic Diseases, 2013, 72, e3-e3.	0.9	3
76	Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. American Journal of Hematology, 2013, 88, 858-861.	4.1	31
77	Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood, 2013, 122, 2477-2486.	1.4	42
78	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica, 2013, 98, 881-887.	3.5	78
79	Safety and Efficacy Of Rituximab In adult's Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry. Blood, 2013, 122, 450-450.	1.4	2
80	Severe Seoul hantavirus infection in a pregnant woman, France, October 2012. Eurosurveillance, 2013, 18, .	7.0	38
81	Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells. Clinical and Experimental Rheumatology, 2013, 31, S65-73.	0.8	8
82	Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis and Rheumatism, 2012, 64, 3788-3798.	6.7	181
83	Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 2499-2503.	6.7	302
84	Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange. Internal Medicine Journal, 2012, 42, 95-98.	0.8	6
85	Switching From Romiplostim to Eltrombopag or Vice Versa for Immune Thrombocytopenia: Efficacy and Safety in 46 Patients. Blood, 2012, 120, 4651-4651.	1.4	1
86	Cost Effectiveness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia.. Blood, 2012, 120, 2157-2157.	1.4	1
87	Failure of Rituximab in Immune Thrombocytopenia Is Associated with the Activation of Splenic CD8 T Cells. Blood, 2012, 120, 623-623.	1.4	1
88	Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood, 2011, 118, 4394-4400.	1.4	98
89	Scalp vein thrombosis mimicking giant cell arteritis relapse. Internal Medicine Journal, 2011, 41, 492-495.	0.8	4
90	Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine, 2011, 78, 241-245.	1.6	39

#	ARTICLE	IF	CITATIONS
91	Cytotoxic Dendritic Cells Generated from Cancer Patients. <i>Journal of Immunology</i> , 2011, 187, 2775-2782.	0.8	23
92	Clinical Spectrum, Treatment, and Outcome of Patients with Type II Mixed Cryoglobulinemia without Evidence of Hepatitis C Infection. <i>Journal of Rheumatology</i> , 2011, 38, 716-722.	2.0	38
93	Multiple anaemic macules and diffuse erythrocytosis revealing mixed cryoglobulinaemia. <i>European Journal of Dermatology</i> , 2011, 21, 269-270.	0.6	5
94	Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 1876-1884.	0.8	58
95	Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine. <i>Haematologica</i> , 2007, 92, e78-e79.	3.5	20
96	Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. <i>Clinical and Experimental Immunology</i> , 2007, 150, 523-530.	2.6	104
97	The inhibition of TNF- α anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. <i>Experimental Cell Research</i> , 2007, 313, 2345-2355.	2.6	35
98	AN UNUSUAL COMPLICATION OF ANTICOAGULATION THERAPY IN AN ELDERLY PATIENT: PITUITARY APOPLEXY WITH REMISSION OF ACROMEGALY. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1798-1800.	2.6	5